Ghezzi L, Exeni A, Velasco J, Barrionuevo T, Coccia P, Ferraris V, Freyle FL, Cisnero D, Rigali MP

Language: Spanish
References: 15
Page: 39-45
PDF size: 163.52 Kb.

ABSTRACT

Hemolytic Uremic Syndrome is an endemic disease in Latin America. Argentina is one of the countries where most cases are reported, with a rate of ten cases per 100,000 children under five years old. It is the first cause of acute renal failure (ARF), and responsible for 9% of kidney transplants. This pathology is characterized by a classic triad: microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The main etiological agent of HUS is the bacterium Shiga toxin-producing Escherichia coli. HUS has an acute mortality lower than 5 %.
There is evidence of the active role of the Shiga toxin in the activation of the complement by binding to factor H. Eculizumab is a monoclonal antibody which inhibits the formation of the membrane attack complex (C5b-9), given its great affinity for C5 of the complement cascade. Its infusion is approved to treat atypical HUS, posing its usefulness to treat severe typical HUS with acute neurological involvement as an alternative to inhibit the complement cascade and stop toxin damage.
We present two pediatric patients with SUH diagnosis with shiga toxin rescue; these patients, who showed severe neurological involvement, were treated with Eculizumab and had a favorable response.

REFERENCES

1. Adragna M, Balestracci A. Capítulo 19. En: Nefrologíapediátrica. 3ª ed. Buenos Aires: Sociedad Argentina dePediatría, 2017, pp. 171-80.

2. Walsh PR, Johnson S. Eculizumab in the treatmentof Shiga toxin haemolytic uraemic syndrome. PediatrNephrol. 2019;34(9):1485-92.

3. Pape L, Hartmann H, Bange FC, Suerbaum S,Bueltmann E, Ahlenstiel-Grunow T. Eculizumabin typical hemolytic uremic syndrome (HUS) withneurological involvement. Medicine (Baltimore).2015;94(24):e1000.

4. Tarr PI, Gordon CA, Chandler WL. Shiga-toxinproducingEscherichia coli and haemolytic uraemicsyndrome. Lancet. 2005;365(9464):1073-86.

5. Trachtman H, Austin C, Lewinski M, Stahl RA. Renaland neurological involvement in typical Shiga toxinassociatedHUS. Nat Rev Nephrol. 2012;8(11):658-69.

6. Pennington H. Escherichia coli O157. Lancet.2010;376(9750):1428-35.

7. Scheiring J, Rosales A, Zimmerhackl LB. Clinicalpractice. Today’s understanding of the haemolyticuraemic syndrome. Eur J Pediatr. 2010;169(1):7-13.

8. Eriksson KJ, Boyd SG, Tasker RC. Acute neurology andneurophysiology of haemolytic-uraemic syndrome. ArchDis Child. 2001;84(5):434-5.

9. Otukesh H, Hoseini R, Golnari P, Fereshtehnejad SM,Zamanfar D, Hooman N, et al. Short-term and longtermoutcome of hemolytic uremic syndrome in Iranianchildren. J Nephrol. 2008;21(5):694-703.

10. Rooney JC, Anderson RM, Hopkins IJ. Clinicaland pathologic aspects of central nervous systeminvolvement in the haemolytic uraemic syndrome. ProcAust Assoc Neurol. 1971;8:67-75.

11. Sheth KJ, Swick HM, Haworth N. Neurologicalinvolvement in hemolytic-uremic syndrome. AnnNeurol. 1986;19(1):90-3.

12. Nathanson S, Kwon T, Elmaleh M, Charbit M, LaunayEA, Harambat J, et al. Acute neurological involvementin diarrhea-associated hemolytic uremic syndrome. ClinJ Am Soc Nephrol. 2010;5(7):1218-28.

13. Rees L. Atypical HUS: time to take stock of currentguidelines and outcome measures? Pediatr Nephrol.2013;28(5):675-7.

14. Gitiaux C, Krug P, Grevent D, Kossorotoff M,Poncet S, Eisermann M, et al. Brain magneticresonance imaging pattern and outcome in childrenwith haemolytic-uraemic syndrome and neurologicalimpairment treated with eculizumab. Dev Med ChildNeurol. 2013;55(8):758-65.

15. Çelakil ME, Yücel BB, Bek K. CFH and CFB mutationsin Shiga toxin-associated haemolytic uraemic syndromein a 6-year-old boy. Paediatr Int Child Health. 2019:1-3.